India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.
A year ago, Sun Pharmaceutical Industries Ltd. paid $48m for California-based InSite Vision Inc., which focuses on developing specialty ophthalmic products. The purchase was a key building block in the strategy of Sun Pharma’s US subsidiary to transition to a specialty company that will in-license and develop branded products for the crucial US market.
Sun head Dilip Shanghvi, a low-profile tycoon who is India’s second-richest person with an estimated worth of $14.9bn, says the...
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
